Cromos Pharma, where the patients are

Janssen

New therapy for advanced prostate cancer approved in Trinidad & Tobago

Monday, April 14, 2014 10:40 AM

The Chemistry, Food and Drugs Division of the Trinidad & Tobago Ministry of Health approved the introduction of Janssen's Abiraterone Acetate, the first orally administered androgen synthesis inhibitor (testosterone) medication for the treatment of patients with metastatic castration-resistant prostate cancer.

More... »

CRF Health eCOA webinar series

CEO Roundtable on Cancer launches data-sharing initiative to accelerate drug development

Thursday, April 10, 2014 01:03 PM

The CEO Roundtable on Cancer has launched Project Data Sphere, a new online oncology data-sharing platform using de-identified cancer patient information with the goal of accelerating drug discovery—by developing more efficient clinical trial protocols, epidemiological studies and, ultimately, new cancer therapies. 

More... »


Janssen expands global cardiovascular research program with three new studies

Monday, March 31, 2014 12:56 PM

Janssen R&D is adding three new clinical trials to its EXPLORER global cardiovascular research program for XARELTO (rivaroxaban), a broadly indicated oral Factor Xa inhibitor. The additional trials will evaluate rivaroxaban for the treatment or prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) in pediatric and other patient populations, including those at risk for DVT or PE due to a concurrent medical illness. The new studies will include more than 11,000 patients in over 30 countries.

More... »

FDA approves Topamax for migraine prevention in adolescents

Monday, March 31, 2014 12:55 PM

The FDA has approved Topamax (topiramate) for prevention (prophylaxis) of migraine headaches in adolescents ages 12 to 17. This is the first FDA approval of a drug for migraine prevention in this age group. The medication is taken on a dailybasis to reduce the frequency of migraine headaches.

More... »

CEOi, NY Academy of Sciences to launch Global Alzheimer's Platform

Wednesday, February 26, 2014 01:21 PM

The Global CEO Initiative (CEOi) on Alzheimer's Disease and the New York Academy of Sciences have convened representatives from industry, academia, government and nonprofits to launch the development of a Global Alzheimer's Platform (GAP), designed to reduce the time and costs of Alzheimer's clinical trials, develop an infrastructure that promotes innovation and assure international collaboration.

More... »

Novartis, Janssen, Eli Lilly, Aptiv Solutions co-found new consortium

Friday, February 21, 2014 11:05 AM

Aptiv Solutions, a global biopharmaceutical and medical device development services company, Novartis Pharma, Janssen Pharmaceuticals and Eli Lilly have joined in co-founding the ADDPLAN DF Consortium. The members of the consortium are collaboratively developing new statistical methodologies for the design of innovative dose-finding clinical trials, with an emphasis on adaptive designs. The ADDPLAN DF Consortium also will focus on enhancing the trial execution technologies required to handle the multiple adaptations integral to complex adaptive dose-finding trials. Aptiv Solutions will integrate and validate the methodologies that emerge from the ADDPLAN DF Consortium into its ADDPLAN DF software for the design, planning and analysis of dose finding trials, in addition to ensuring that these designs can be easily implemented through its proprietary execution platform.

More... »

Critical Path Institute receives grant for tuberculosis treatments

Wednesday, February 12, 2014 01:31 PM

The Critical Path Institute, an independent nonprofit that catalyzes innovative ideas to accelerate the speed of drug and medical product development, has received a three-year grant from the Bill & Melinda Gates Foundation. The grant will be used to develop quantitative mathematical models to optimize the design of clinical trials and tackle challenges facing the development of effective tuberculosis (TB) treatments.  

More... »

Janssen R&D launches novel trial data sharing agreement with Yale School of Medicine

Thursday, January 30, 2014 10:49 AM

Johnson & Johnson subsidiary Janssen Research and Development has entered into a novel agreement with Yale School of Medicine's Open Data Access (YODA) Project to extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine. 

More... »

Janssen forms new group targeting unmet global health needs

Friday, January 24, 2014 11:47 AM

Janssen, the pharmaceutical companies of Johnson & Johnson, has formed Janssen Global Public Health (Janssen GPH), a new group unifying Janssen's commitment to research, develop and deliver transformational medicines to address the world's greatest unmet public health needs.

More... »

Capricor Therapeutics, Janssen Biotech collaborate

Monday, January 6, 2014 12:00 PM

Capricor Therapeutics, a publicly traded biotechnology company, has signed a collaboration and exclusive license option with Janssen Biotech for development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs